| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2583 | 2015 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1660* | 2020 |
| Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ... Nature medicine 24 (5), 679-690, 2018 | 1544 | 2018 |
| Integrated genomic characterization of pancreatic ductal adenocarcinoma BJ Raphael, RH Hruban, AJ Aguirre, RA Moffitt, JJ Yeh, C Stewart, ... Cancer cell 32 (2), 185-203. e13, 2017 | 1518 | 2017 |
| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1097 | 2016 |
| The evolutionary history of 2,658 cancers M Gerstung, C Jolly, I Leshchiner, SC Dentro, S Gonzalez, D Rosebrock, ... Nature 578 (7793), 122-128, 2020 | 847 | 2020 |
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ... Nature communications 8 (1), 1324, 2017 | 742 | 2017 |
| Comprehensive molecular characterization of pheochromocytoma and paraganglioma L Fishbein, I Leshchiner, V Walter, L Danilova, AG Robertson, ... Cancer cell 31 (2), 181-193, 2017 | 625 | 2017 |
| Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ... New England Journal of Medicine 374 (1), 54-61, 2016 | 524 | 2016 |
| A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer P Polak, J Kim, LZ Braunstein, R Karlic, NJ Haradhavala, G Tiao, ... Nature genetics 49 (10), 1476-1486, 2017 | 488 | 2017 |
| Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ... Cancer discovery 7 (3), 252-263, 2017 | 462* | 2017 |
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature medicine 25 (9), 1415-1421, 2019 | 402 | 2019 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 378 | 2020 |
| Paired exome analysis of Barrett's esophagus and adenocarcinoma MD Stachler, A Taylor-Weiner, S Peng, A McKenna, AT Agoston, ... Nature genetics 47 (9), 1047-1055, 2015 | 368 | 2015 |
| Integrated molecular characterization of uterine carcinosarcoma AD Cherniack, H Shen, V Walter, C Stewart, BA Murray, R Bowlby, X Hu, ... Cancer cell 31 (3), 411-423, 2017 | 356 | 2017 |
| Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes SC Dentro, I Leshchiner, K Haase, M Tarabichi, J Wintersinger, ... Cell 184 (8), 2239-2254. e39, 2021 | 288 | 2021 |
| TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 277 | 2019 |
| Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies R Guièze, VM Liu, D Rosebrock, AA Jourdain, M Hernández-Sánchez, ... Cancer cell 36 (4), 369-384. e13, 2019 | 263 | 2019 |
| Comprehensive assessment of cancer missense mutation clustering in protein structures A Kamburov, MS Lawrence, P Polak, I Leshchiner, K Lage, TR Golub, ... Proceedings of the National Academy of Sciences 112 (40), E5486-E5495, 2015 | 232 | 2015 |
| Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma RK Gopal, K Kübler, SE Calvo, P Polak, D Livitz, D Rosebrock, PM Sadow, ... Cancer Cell 34 (2), 242-255. e5, 2018 | 215 | 2018 |
Gad GetzMassachusetts General Hospital and Broad Institute of Harvard and MITVerified email at broadinstitute.org
